Role of homocysteine in the development and progression of Parkinson’s disease

Fan, Xiaoyan; Zhang, Lixia; Li, Haijun; Chen, Guang; Qi, Gangqiao; Ma, Xueqiang; Jin, Yinlong

doi:10.1002/acn3.51227

Cited by 54 publications

(38 citation statements)

References 55 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated plasma homocysteine levels are known found to be associated with PD 33 and several in-vivo studies have revealed the beneficial results of a low methionine diet on neurodegenerative diseases 33 . In our clinical trial, plasma levels of S-adenosylhomocysteine as well as 2,3-dihydroxy-5-methylthio-4-pentenoate and N-acetyl taurine were significantly decreased on Day 84 vs Day 0 in the CMA group (Figure 3B, Dataset S4).…”

Section: Resultsmentioning

confidence: 99%

Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease

Yuluğ¹,

Altay

et al. 2021

Preprint

View full text Add to dashboard Cite

The neuropathologic hallmarks of Parkinson's disease (PD) are associated with mitochondrial dysfunction and metabolic abnormalities. We have reported that the Combined Metabolic Activators (CMA), consisting of L-serine, nicotinamide riboside, N-acetyl-L-cysteine, and L-carnitine tartrate can be used in treating metabolic abnormalities. These metabolic activators are the precursors of nicotinamide adenine dinucleotide (NAD+) and glutathione (GSH) and used in activation of mitochondrial and global metabolism. We have performed a placebo-controlled, phase-2 study in Alzheimer's disease (AD) patients and reported that the cognitive functions in AD patients is significantly improved 29% in the CMA group whereas it is improved only 14% in the placebo group after 84 days of CMA administration. Here, we designed a randomized, double-blinded, placebo-controlled, phase-2 study in PD patients with CMA administration. We found that the cognitive functions in PD patients is significantly improved 21% in the CMA group, whereas it is improved only 11% in the placebo group after 84 days of CMA administration. We also found that the administration of CMA did not affect motor functions in PD patients. We performed a comprehensive multi-omics analysis of plasma proteins and metabolites, and revealed the molecular mechanism associated with the treatment of the patients. In conclusion, our results show that treating PD patients with CMAs leads to enhanced cognitive function, as recently reported in AD patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease

Yuluğ¹,

Altay

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…34 High Hcy levels in PD patients can affect many pathways including gene defects, apoptosis, oxidative stress and DNA damage. 22 Hcy may be neurotoxic to the SN due to disruption of the balance of striatal activity, but experimental studies have shown it. The results of experimental studies are different from studies conducted on PD patients.…”

Section: Discussionmentioning

confidence: 99%

Individual susceptibility has a major impact on strong association between oxidative stress, defence systems and Parkinson's disease

Karahalıl

Salihoğlu

Orhan

et al. 2021

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Numerous studies have demonstrated a potential role of OCM in the development of PD [ 226 ]. In accordance with AD, elevated plasma Hcy is evident in approximately 30% of PD patients and is suggested to be involved in the onset and progression of PD [ 227 ]. Hyper-homocysteinemia in PD patients may be aggravated due to the frequent administration of L-DOPA as a treatment to replenish dopamine loss.…”

Section: One-carbon Metabolism and Neurodegenerationmentioning

confidence: 99%

One-Carbon Metabolism: Pulling the Strings behind Aging and Neurodegeneration

Lionaki

Ploumi

Tavernarakis

2022

Cells

View full text Add to dashboard Cite

One-carbon metabolism (OCM) is a network of biochemical reactions delivering one-carbon units to various biosynthetic pathways. The folate cycle and methionine cycle are the two key modules of this network that regulate purine and thymidine synthesis, amino acid homeostasis, and epigenetic mechanisms. Intersection with the transsulfuration pathway supports glutathione production and regulation of the cellular redox state. Dietary intake of micronutrients, such as folates and amino acids, directly contributes to OCM, thereby adapting the cellular metabolic state to environmental inputs. The contribution of OCM to cellular proliferation during development and in adult proliferative tissues is well established. Nevertheless, accumulating evidence reveals the pivotal role of OCM in cellular homeostasis of non-proliferative tissues and in coordination of signaling cascades that regulate energy homeostasis and longevity. In this review, we summarize the current knowledge on OCM and related pathways and discuss how this metabolic network may impact longevity and neurodegeneration across species.

show abstract

Role of homocysteine in the development and progression of Parkinson’s disease

Cited by 54 publications

References 55 publications

Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease

Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease

Individual susceptibility has a major impact on strong association between oxidative stress, defence systems and Parkinson's disease

One-Carbon Metabolism: Pulling the Strings behind Aging and Neurodegeneration

Contact Info

Product

Resources

About